GlassScriptPhysician profile
Chandra A Adams
NPI 1104858034
$1,580.11
in general payments reported to CMS, 2019-2025
26 companies · $435 in 2025
The $435 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $107 · 2021: $79.07 · 2022: $156 · 2023: $321 · 2024: $338 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $242.75 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $198.06 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $195.78 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $171.22 | 2019-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Exeltis, USA INC. | $116.42 | 2019-2025 | Slynd |
| Pfizer INC. | $78.56 | 2023-2024 | |
| Abbvie INC. | $69.07 | 2019-2023 | |
| Channel Medsystems, INC. | $67.77 | 2023-2025 | |
| Shield Therapeutics INC | $52.33 | 2023-2024 | Accrufer |
| Myovant Sciences INC. | $43.00 | 2022 | |
| Applied Medical Resources Corporation | $35.48 | 2022 | |
| Therapeuticsmd, INC. | $35.43 | 2021-2022 | |
| Agile Therapeutics, INC. | $33.50 | 2022-2024 | Twirla |
| Viiv Healthcare Company | $30.38 | 2024 | Apretude |
| Alydia Health | $25.91 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $24.14 | 2023 | Phexxi |
| Coopersurgical, INC. | $23.28 | 2024 | Paragard T 380a |
| Astellas Pharma US INC | $21.27 | 2025 | Veozah |
| Lupin INC. | $18.37 | 2020 | |
| Optumhealth Care Solutions, LLC | $17.40 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Teleflex LLC | $17.33 | 2025 | Quikclot |
| Janssen Biotech, INC. | $16.95 | 2025 | Tremfya |
| Smith+Nephew, INC. | $15.80 | 2019 | |
| Lsi Solutions INC | $15.07 | 2025 | Fornisee |
| Merck Sharp & Dohme LLC | $14.84 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.